The company has a pipeline of small molecule drug candidates for treating various human diseases, including Alzheimer's disease, type 2 diabetes, muscle weakness, and inflammatory disorders. Its lead candidate, azeliragon, has shown promising results in Phase 2 clinical trials for Alzheimer's disease and has been granted Fast Track Designation. The company is also developing TTP399, a drug candidate for type 2 diabetes, which has shown positive results in a Phase 2a study. Additionally, vTv Therapeutics has over three other programs in different stages of clinical development.